Former FDA Commissioner Stephen Hahn has been named CEO of Nucleus RadioPharma, a contract developer and manufacturer specializing in radiopharmaceuticals and radioligand therapies. These therapies deliver targeted radioactive isotopes directly to cancer cells, aiming to minimize collateral tissue damage compared to conventional radiation treatments. Hahn’s leadership at Nucleus begins a return to his roots in radiopharmaceutical science, strengthening the company’s position in next-generation oncology treatment development and manufacturing.